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Loss of pancreatic β cells occurs in both type 1 diabetes mellitus (DM), characterized by 51 autoimmune destruction of β cells, and type 2 DM in which β cell dysfunction and 52 deficiency occur in the context of peripheral insulin resistance. One strategy to restore β 53 cell mass has been focused on the discovery of molecules capable of inducing β cell 54 proliferation. 55 Studies of the human pancreas have found that β cell proliferation peaks 56 neonatally at about 1-3% then sharply declines after the first year of life eventually 57 approaching near 0% and remains at this low level throughout adulthood (17, 21, 24, 58 27). The extremely low proliferation rate in adult human β cells suggests that even 59 though these cells retain expression of factors required for cell cycle entry, the 60 progression of the cell cycle is halted by cell cycle inhibitors (11, 14, 15) . A recent study 61 by Robitaille, et al. identified p18 and p21 as cell cycle inhibitors required to maintain β 62 cell quiescence, and demonstrated that silencing these inhibitors facilitates cell cycle 63 entry in human β cells (32) . Furthermore, several studies have established that 64 overexpressing cyclins and/or cyclin-dependent kinases (CDKs) can induce adult 65 human β cell proliferation and lead to an increased number of β cells (13, 16, 37, 39) . 66 These findings suggest that factors or compounds capable of overcoming cell cycle 67 inhibition could reactivate adult human β cell replication. 68 The majority of studies focused on understanding and identifying regulators of β 69 cell regeneration have been performed in rodent models, and more recently some high- enough to detect changes in proliferation. Even at its peak neonatally, human β cell 82 proliferation only reaches ~2%, and this physiological limit has been proposed as a 83 maximum target for therapeutic interventions (44) . However, identifying compounds 84 able to stimulate β cell proliferation from near zero to no more than 2% requires 85 protocols with high sensitivity and specificity for the detection of proliferating β cells. (2) 86 Suitable human β cells lines are not available, requiring the use of islets from human 87 donors. However, the functional variability due to both intrinsic (e.g., genetics, race, age, 88 BMI) and extrinsic (e.g., isolation protocol, time in culture) factors, makes it difficult to 89 consistently reproduce results from a small sample size (22, 42) . Previous work by our 90 group and others has demonstrated the importance of pre-screening human islets for 91 their quality to minimize extrinsic differences between preparations, thereby maximizing 92 experimental reproducibility (22, 25 assessed in a dynamic cell perifusion system for insulin secretory response to 120 determine islet quality as previously described (12, 22) ( Figure 1A ). Briefly, sixty purified, plates in all of our experiments. All plated cells were cultured at 37°C and allowed to 156 adhere for 24 hours prior to compound treatment.
Compound preparation and islet cell treatment
158
Plated cells were exposed to the compounds listed in Table 2 ). 3). Baseline β cell proliferation at basal (5 mM) glucose was 0.03±0.01%, which is 300 comparable to reported proliferation indices of adult human β cells from autopsy 301 samples, and increased to 24.5±5.5% with transduction ( Figure 3C ) (17, 21, 24, 27).
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Glucose concentration had no effect on human β cell proliferation of either control or 303 transduced β cells ( Figure 3C ). proliferation achieved using our method should be used as a threshold for deciding 397 which compounds should be developed further. 398 Using an adult human islet cell culture system to assess human β cell Another limitation of studying human β cell proliferation in vitro is the requirement 427 of using surrogate proliferation markers because it is not feasible to definitively measure 428 an increase in cell number due to the low replication rate in these cells. We used Ki67 to 429 Aamodt, et al. 21 identify proliferating cells in our culture system, which is expressed in cells that have 430 entered the cell cycle; however, the method we describe here can also be adapted to 431 substitute other proliferation markers (e.g., BrdU) (32) . While it would be ideal to be able 432 to directly identify an increase in human β cell number, the purpose of this study was to 433 develop a method to screen for molecules that may induce proliferation and which 434 therefore merit further validation as mitogenic agonists. Comparisons between controls or compound treatments at 5 mM vs. 11 mM glucose 542 were not statistically significant in any compound or control tested, and there was no 543 difference between vehicle controls (P=0.13-0.62); n=3-6 donors/treatment condition. D.
E.
F.
G.
Image analysis with Bitplane Imaris software H.
C.
à Insulin or C-peptide à Pdx1 à Ki67
Figure 1 A.
B.
Figure 3
